Anti-CD20 CART-transduced T cells (Cellular Biomedicine Group)

抗CD20 CART转导的T细胞

Report date: 2023/05/05 17:34:47

Base Information

Drug NameAnti-CD20 CART-transduced T cells (Cellular Biomedicine Group)
Drug Alias NameAnti-CD20 CART cells (Cellular Biomedicine Group)Genetically engineered lymphocyte therapy (Cellular Biomedicine Group)Anti-CD20 chimeric antigen receptor T cell therapy (Cellular Biomedicine Group)CAR-CD20 T cell therapy (Cellular Biomedicine Group)CBM-CD20 1 +[7] 
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vector
Mechanisms of ActionT lymphocyte replacementsAnti-CD20
TargetsB-lymphocyte antigen CD20
Therapy Area/IndicationsHematologic NeoplasmsLymphoma, Mantle-CellLymphoma, Follicular +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesPla General Hospital
China Registration ClassN/A

Develop Information

Active CompaniesPla General HospitalCellular Biomedicine (Shanghai) Co Ltd
Inactive CompaniesN/A
Active IndicationsLymphoma, B-CellLeukemia
Inactive IndicationsHematologic NeoplasmsLymphoma, Mantle-CellLymphoma, Follicular +[8] 

Other Information

ATC CodeN/A
Related LinksN/A